Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) major shareholder Movers Lab Fund I. Lp Prime sold 270,964 shares of the stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $2.97, for a total transaction of $804,763.08. Following the completion of the sale, the insider now directly owns 9,180,710 shares in the company, valued at $27,266,708.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.

Vaxxinity Trading Up 0.5 %

Shares of NASDAQ:VAXX opened at $2.00 on Thursday. Vaxxinity, Inc. has a 52 week low of $1.26 and a 52 week high of $10.57. The company's 50 day moving average is $1.73 and its two-hundred day moving average is $2.14. The company has a current ratio of 3.33, a quick ratio of 3.33 and a debt-to-equity ratio of 0.12. The company has a market cap of $252.11 million and a PE ratio of -1.61.

Institutional Investors Weigh In On Vaxxinity

A number of large investors have recently modified their holdings of VAXX. Bank of America Corp DE grew its position in shares of Vaxxinity by 7,829.0% in the 1st quarter. Bank of America Corp DE now owns 15,858 shares of the company's stock valued at $68,000 after buying an additional 15,658 shares during the last quarter. Hollencrest Capital Management purchased a new position in shares of Vaxxinity in the 2nd quarter valued at $31,000. Clarius Group LLC purchased a new position in shares of Vaxxinity in the 2nd quarter valued at $31,000. Truist Financial Corp purchased a new position in shares of Vaxxinity in the 2nd quarter valued at $33,000. Finally, First Republic Investment Management Inc. purchased a new position in shares of Vaxxinity in the 3rd quarter valued at $394,000. 20.73% of the stock is owned by hedge funds and other institutional investors.

About Vaxxinity

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD.

Recommended Stories

• Get a free copy of the StockNews.com research report on Vaxxinity (VAXX)
• Are Investors Hearing The End Of Spotify's Downtrend?
• The Question of a Fed Pivot Isn't If, It's When, Here's Why
• Top 10 Searched Stocks on MarketBeat All-Access
• 3 Dividend Kings With Royally Good Upside
• Institutions Sell The Rallies In Toll Brothers Stock

Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.